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Abstract  We  present  the  case  of  a  58-year-old  male  patient  who  had  symptoms  of  anxiety  after
witnessing  a  case  of  social  violence  in his  community  in 2005.  After  that,  he  presented  symptoms
of Parkinson  Disease  and in 2006  we  established  this  as the  main  diagnosis.  In  2009  he  presented
neuropsychiatric  symptoms  such  as  apathy,  anhedonia,  social  isolation,  blunted  affect,  visual
and auditory  hallucinations,  paranoid  delusions,  soliloquies,  and  the  false belief  that  his  wife
and daughter  had been  replaced  by  identical  impostors.  We  established  the  diagnosis  of  Capgras
Syndrome.  This  case  is clinically  relevant  because  of  the  presentation  of  its symptoms,  its
evolution  and  its presenting  comorbidity.
©  2014  Universidad  Autónoma  de Nuevo  León.  Published  by  Masson  Doyma  México  S.A.  All  rights
reserved.
Introduction
The  ability  to recognize  faces  and  discriminate  those  which
are  not  familiar  to  us  is  there  since  birth,  and  it  is  developed
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and  perfected  through  the  first years  of life. Delusional
misidentification  syndromes  are  a  group  of  phenomena  in
which  patients  erroneously  identify  familiar  people  or  places
or  even  themselves,  believing  said  objects  or  people  to  have
been replaced  or  transformed.  There are  several  subtypes,
however,  most  authors  divide  it  into  4 main  syndromes
(Capgras  syndrome,  Frégoli  syndrome,  Intermetamorphosis
syndrome  and  syndrome  of  subjective  doubles),  Capgras
syndrome  being  the  most  common  among  these  syndromes.1
Joseph Capgras  described  the  first  case  of  a syndrome
characterized  by  the  delusional  belief  that  a close  relative
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has  been  replaced  by  an impostor.  In  the beginning,  it was
believed  to  be  associated  to  a higher  degree  with  psychi-
atric  disorders,  but in fact it is  more  frequently  associated
with  neurodegenerative  diseases,  especially  with  Lewy body
disease,  and  it  is  commonly  found  in association  with  visual
hallucinations.2 In the  case  of  Capgras  syndrome,  there  is
not  only  the  misidentification  of  someone  familiar  to  them,
but  a  delusional  belief  that  the  person  has  been replaced  by
a  double  that  is  not quite  exact.  Study  of  the causes  has been
closely  linked  to  the analysis  of  patients  with  brain  injuries
which  would  have  developed  prosopagnosia.3 This  percep-
tual  disorder  causes  the patient  to  be  unable  to  recognize
faces  in  a  consistent  way,  despite  the fact that  he/she  is
able  to  recognize  visual  objects.4
Continuing  along  the lines  of  the study  of Capgras  syn-
drome,  starting  from  the prosopagnosia  phenomenon,  it  has
been  suggested  that  there  would  be  a ‘‘mirror  image’’  of
prosopagnosia,  in  a  way  that, although  the  conscious  ability
to  recognize  faces  would  be  intact,  there  would  be  damages
to  the  system  that  produces  automatic  emotional  excite-
ment  when  observing  familiar  faces.5 This  finding  was  later
confirmed  in patients  with  a Capgras  syndrome  diagnosis.
Traditionally,  the origin  of  Capgras  syndrome  was  consid-
ered  to  reside  in  a  psychodynamic  base;  the premise  was
that  people  who  received  a  great  deal  of  affection  from  the
patients  were  also  recipients  of their  ambivalence,  which
made  them  the object  of  the  projections  and  led to the
patient’s  psychological  disintegration.
On  the  other  hand,  in addition  to  prosopagnosia,  Capgras
syndrome  has  been  linked  with  multiple  pathologies.  It  has
been  described  in  psychiatric  as  well  as  organic  disorders.
Within  psychiatric  profiles,  it is  common  to  find  this delusion
in  paranoid  schizophrenia,  as  well  as  psychotic  depression,
delusional  disorders,  schizoaffective  disorder  or  bipolar  dis-
order,  with  a  frequency  of  1--15% in  psychotic  patients.
Regarding  the  organic  conditions  that  occur  in Capgras
delusion,  this  appears  mainly in various  types  of  demen-
tia  like  Alzheimer,  Lewy  bodies  and  Parkinson,  as  well  as
posterior  to  brain  injuries.  It  is  followed  among  other  con-
ditions  by  ictus,  epilepsy,  chronic  alcoholism  cases  and
encephalitis.6
Capgras  syndrome  has  been  considered  a  type of paranoid
psychosis  more  frequently  linked  to  Lewy  body  dementia,
as  well  as  psychiatric  illnesses  like  schizophrenia.  Neverthe-
less,  there  are  reports  in medical  literature  that  even  link  it
to  dopaminergic  deficiency,  which  appears  during  the ‘‘off’’
states,  solving  it  with  an increment  in L-dope  and  less  fre-
quently  in  an isolated  form  as a psychiatric  manifestation
of  Parkinson’s  disease.7 Below,  we  describe  a peculiar  case
of  a  patient  who  presented  Parkinson’s  disease  and  Capgras
syndrome  simultaneously.
Clinical case
The  patient  is  a 58-year-old  male  with  a history  of  systemic
arterial  hypertension  (since  he  was  45  years  old),  without
a  history  of any  other  major  health  issue.  His  symptoms
began  in  2004  with  a  right  upper  limb  tremor  which  did
not  affect  his everyday  life,  and  thus  was  not given  impor-
tance.  In 2005  he  witnessed  a situation  of  social  violence
having  been  caught  in  a  crossfire  and  having  his  workplace
attacked  with  a  grenade.  As  a  result,  he  began  displaying  the
following  symptoms:  anxiety,  fear,  recurrent  memories  of
the  event,  affective  bottling,  hypervigilance  and  avoidance
behavior,  with  a significant  decline  in  his  work  and  social
activity.  He  was  diagnosed  with  acute  stress  disorder  and
began  treatment  with  50  mg  of  sertraline  every  24  h,  with  a
remission  of  symptoms.  Subsequently,  other  symptoms  char-
acterized  by  bradykinesia  appeared,  with  an increase  in the
right  upper  limb  rest  tremor,  fine  motor  clumsiness  and  gait
and  posture  alterations  being  asymmetrical  with  uncoordi-
nated  arm  movement.  A  Parkinson’s  disease  diagnosis  was
established  in 2006. In 2009  the  patient  displayed  neuropsy-
chiatric  signs  and  symptoms,  apathy,  anhedonia,  a  tendency
to  isolation,  affective  bottling,  and later  aural  and  visual
hallucinations  with  paranoid  content,  soliloquies,  as  well
as  a  false belief  that  his  wife  and  daughter  were  not  them
but  had  been  replaced  by  other  people,  thus  integrating  a
Capgras  syndrome.
The following  clinimetrics  were performed:  The  Schwab
&  England  Activities  of  Daily  Living  Scale, which  evaluates
the  patient’s  functional  state,  with  a value  of  10%,  mean-
ing the  patient  is  ‘‘Totally  dependent,  harmless;  completely
handicapped’’.  Hoehn  and Yahr  evaluation  scale,  a  descrip-
tive  staging  scale  of  the  progression  of  Parkinson’s  disease
symptoms,  placing  the  patient  in a  stage  4: Severe  dis-
ability;  still  able  to  walk  or  stand  unassisted.  Freezing  and
‘‘on-off’’  unpredictable  (Stages  1--5, where  stage  1: mini-
mal  or  no  functional  disability  and stage  5:  the  patient  is
confined  to  a bed).  Montreal  Cognitive  Assessment  battery
(MoCa)  evaluates  mild  cognitive  impairment,  with  a score
of  11,  corresponding  to  a moderate  cognitive  impairment
(normal  range  of 24--30).  Hamilton  anxiety  rating  scale  of
10  (mild  anxiety).  Hamilton  depression  scale  with  5 points
(not depressed).  Folstein  Mini-Mental  State  Exam  with  17
points,  corresponding  to  moderate  impairment.
Treatment  was  begun  with  levodopa/carbidopa
250  mg/25  mg orally,  ½ pill  every  6  h,  and amantadine
100  mg  orally  ½ tbsp  every  8  h  with  a  positive  control  of
Parkinsonism  symptoms.  Regarding  psychotic  symptoms,
we  began treatment  with  quetiapine  150 mg with  positive
results.  Currently  the  patient  continues  with  the  same
treatment  and  is  stable,  with  good  control  of  Parkinson’s
symptoms,  in addition  to  not  presenting  current  active
psychosis.
Discussion  and conclusions
The  presence  of  hallucinations  and  delusions  is frequent
in Parkinson’s  disease,  affecting  around  20--30%  of  the
patients.8 Psychotic  symptoms  have  been  linked to  the  dis-
ease  before  there  were  treatments  for  it,  but  its  prevalence
has  considerably  risen  since  the generalization  of the use
of  dopaminergic  stimulation.9 There  also  have  been  reports
of  the presence  of  transient  neurocognitive  changes,  sec-
ondary  to  the placement  of  a deep cerebral  stimulator  for
resistant  Parkinson’s,  causing  symptoms  characteristic  of
Capgras  syndrome.10
One  of  the most relevant  intrinsic  factors  in the devel-
opment  of  psychosis  is  the  cholinergic  deficit.  Other
precipitant  and  risk  factors  linked  to  the  disease  itself
are  the  age  of onset, length,  presence  of  depression  and
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especially  the  presence  of cognitive  impairment,  because
Capgras  syndrome  appears  in  the later  stages  of dementia
in  Parkinson’s,  which  results  in stressing  situations  for the
patients  and  even  more  for  the caregivers.11
The  most  important  factor  is  the  direct  and indirect
stimulation  of  the corticolimbic  dopaminergic  receptors.
In  fact,  these  phenomena  may  appear  even  in patients
being  treated  with  L-Dopa  or  dopaminergic  agonists  in early
stages,  although  its  frequency  increases  considerably  in
more  advanced  patients  and  in  patients  with  complications,
especially  if  they  develop  dementia.  Recent  processing
models  highlight  the  dissociation  between  recognition  and
emotional  response,  based  --  from  the neurobiological  point
of  view  -- on  the disconnection  between  the frontal  lobe
and  the  right  temporal  and limbic  regions,  along with
the  bilateral  frontal  damage.  Some  theories  suggest  a
two-way  intervention  as  an explanation,  one  lateral  non-
cortical  and  the other  subcortical,  located  in  the right
hemisphere.12
Evidence  that  not  all patients  with  right  hemisphere
affectation  develop  a  delusional  syndrome  has  led to  suggest
the presence  of  a positive  mechanism  creator  of  delusions,
which  would  require  at least  a certain  preservation  of the
left  hemisphere.  This  usually  acts  to  inhibit  the  right  side;
it  tries  to give  coherence  and  sense  and interpret  dissonant
information  between  recognition  and  absence  of  familiarity,
thus  its  affectation  would  lead  to  delusion.13
Moreover,  the  monothematic  delusion  two-factor  theory,
among  which  there  is  the Capgras  syndrome,  suggests  that
the  genesis  is caused  by a double  failure:  a right  hemisphere
injury,  probably  in  the  ventromedial  zone of  the  right-frontal
lobe,  in  addition  to  the  failure  of  the beliefs  comparison
mechanism,  which  produces  delusion  persistence  in spite
of  evidence  against  it,  sustained  also  by  the  right  frontal
lobe.14 The  positive  mechanism  in  this  case  would  be the
beliefs  evaluation  system,  similar  to  the  reality  monitoring
functions.15
On  the  other  hand,  psychiatric  manifestations  of  Parkin-
son’s  disease  are:  depression  and  anxiety.  Mood  disorders
are  probably  Parkinson’s  disease’s  most  frequent  symptoms,
so  much  that  they  may  precede  motor  symptoms  in  up  to
30%  of  cases.16
Significant  depression  prevalence  presents  itself  in  more
than  double  the number  of  patients  with  Parkinson’s  (37%)
than  what  is  normally  found  in other  diseases  (18%).  Less
severe  forms  of  depression  are more  frequent  than  major
depression,  however;  the latter  occurs  in  5% of patients.
Despite  everything,  the depressive  symptomatology  dis-
played  in  this  context  goes  beyond  the simple  expected
reaction  caused  by  suffering  an upsetting  disease  and  being
mostly  disabled  to  a  greater  or  lesser  degree.  Changes  in the
serotoninergic  system  play  a major  role,  a  link with  nora-
drenergic  transmission,  based  on  the  presence  of a deficit
of  noradrenergic  neurons  in the  locus  coeruleus.  There  is
a  dopamine  deficit  in  mesocortic-limbic  projections  and  of
dopaminergic  cells  in  the ventral  tegmentum  in depressed
parkinsonians.17
The  anxiety  disorders  are manifested  through  agitation,
chronic  anxiety,  panic attacks  and obsessive-compulsive
disorders.  The pathogeny  of  anxiety  is  explained  by  the
increment  caused  by levodopa  of  the  catecholamine  and  its
metabolites  of  the brain.  It  is  usually  linked  to  the  amount
and duration  of  treatment  and  it is  more  frequent  in the
‘‘off’’  periods.18
Chronic  anxiety  can  be  an  exclusive  manifestation  of the
‘‘off’’  periods  and  may  be present  during  the whole  day.
Due  to  therapeutic  implications,  it  is  important  to  deter-
mine  this symptom’s  presentation  profile,  because  in the
case  of being  secondary  to  the increment  of catecholamine
by  levodopa,  dopaminergic  treatment  must  be adjusted,  in
addition  to  applying  psycho-pharmaceutics.19 Panic  attacks
are usually  linked  to  prolonged  treatments  with  levodopa.
They  constitute  a rare  complication  and  occasionally  occur
in  concurrence  with  the  ‘‘off’’  periods  of  levodopa  depen-
dents,  much  later  than  dyskinesia  and  motor  fluctuations.
In this  case,  the  patient  has  presented  the three  most
frequent  types  of  psychiatric  manifestations,  although  what
draws  attention  has  been  the Capgras  syndrome,  because
this  syndrome  constitutes  a complex  process  that  is  not
limited  to  a simple  facial  processing  problem,  but  a mul-
tiple  cerebral  dysfunction  which sustains  it,  since  it may
become  chronic.  Due  to  the high  frequency  of the psychi-
atric  manifestations  of  Parkinson’s  disease,  linked  or  not  to
medical  treatment,  it is  important  to  know  the  syndromes
associated  with  the  ‘‘off’’  periods  of  the disease  and  to  know
how  to  tell  them  apart  from the  medications’  side  effects
and  psychotic  symptoms  of  other  origin  in  order  to  imple-
ment  the proper  treatment,  because  it  impacts  quality  of
life  and its  functional  prognosis.  Clinical  interviews  are  basic
for  establishing  the order  of  the symptoms.
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